STOCK TITAN

Pacira Biosciences Inc - PCRX STOCK NEWS

Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.

Pacira BioSciences Inc (NASDAQ: PCRX) is a leader in non-opioid pain management, offering innovative therapies that reduce reliance on traditional opioids. This page provides investors and healthcare professionals with timely updates on the company’s latest developments, including regulatory milestones, clinical advancements, and strategic initiatives.

Access PCRX’s official press releases, earnings reports, and analysis of key events shaping its position in the specialty pharmaceutical sector. Track updates on flagship products like EXPAREL® (long-acting local anesthetic) and iovera® (targeted cold therapy), along with emerging pipeline candidates such as PCRX-201 for osteoarthritis.

Discover how Pacira’s proprietary drug delivery platforms and commitment to evidence-based solutions address critical needs in postsurgical recovery and chronic pain management. Stay informed about partnerships, regulatory approvals, and market expansion efforts driving the company’s growth.

Bookmark this page for direct access to PCRX’s verified news, ensuring you never miss developments impacting its role in transforming pain treatment. Visit regularly to monitor progress in non-opioid innovation and regenerative health solutions.

Rhea-AI Summary

Pacira BioSciences, Inc. announced the pricing of $250 million in convertible senior notes due 2029, with an option for additional notes. The net proceeds are estimated to be around $242 million, to be used for various purposes. The notes will bear interest at 2.125% per year and can be converted under certain conditions. Pacira also entered into capped call transactions to reduce potential dilution. The offering is made to qualified institutional buyers under Rule 144A.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences, Inc. announced a proposed offering of $250.0 million aggregate principal amount of convertible senior notes due 2029. The company intends to use the net proceeds for various purposes, including repurchasing existing notes, funding capped call transactions, and repurchasing shares of common stock. The offering is aimed at qualified institutional buyers and will involve privately negotiated capped call transactions to reduce potential dilution to common stock. Overall, the offering is part of Pacira's strategic financial planning to support its corporate goals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences, Inc. (Nasdaq: PCRX) reported strong financial results for Q1 2024, with total revenues of $167.1 million. Net product sales included $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera°. The company also announced a $150 million share repurchase program, presented positive efficacy and safety data for PCRX-201, granted RMAT designation to PCRX-201, and secured three new EXPAREL patents. Financially, GAAP net income was $9.0 million, non-GAAP net income was $31.1 million, and adjusted EBITDA was $44.6 million. Pacira reaffirmed its 2024 financial guidance with a strong outlook for the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.84%
Tags
buyback earnings
Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024. The event will be held in New York, with live audio accessible on the company's website. A replay will be available for two weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
conferences
-
Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ:PCRX) will release its first quarter financial results on May 7, 2024, followed by a live conference call and webcast. Participants can dial 1-800-715-9871 (passcode 6363041) or 1-646-307-1963 for international callers. The webcast will be available on the Pacira website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences earnings
-
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The event will take place on Monday, April 8, 2024, at 8:00 AM ET. Live audio can be accessed on the company's website with a replay available for two weeks after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
Rhea-AI Summary
Pacira BioSciences, Inc. receives RMAT designation from FDA for PCRX-201 gene therapy product candidate for osteoarthritis. Positive Phase 1 study results show efficacy for at least 52 weeks. Additional data to be presented at OARSI 2024. RMAT designation expedites development process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference. The event will take place on March 13, 2024, in Miami, at 1:35 PM ET. Live audio can be accessed on the company's website. A replay will be available for two weeks post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
conferences
-
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) reported record revenues of $675 million in 2023, with full-year GAAP net income of $42 million and adjusted EBITDA of $214 million. EXPAREL surpassed the 14 million patient mark, and the FDA approved new manufacturing suite and label expansions. The company appointed Frank D. Lee as CEO, aiming for long-term growth and operational excellence in pain management solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) will release its Q4 and full-year 2023 financial results on February 29, 2024. A live conference call and webcast will follow, allowing participants to engage in a Q&A session. The event will be accessible via webcast and replay options for those unable to join live.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences earnings
Pacira Biosciences Inc

Nasdaq:PCRX

PCRX Rankings

PCRX Stock Data

1.14B
44.69M
3.18%
111.99%
12.66%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
TAMPA